Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Iparomlimab + Tuvonralimab with Chemotherapy in Locally Advanced HNSCC
ChiCTR2500113105Phase 4Not yet recruiting
- Sponsor
- Shandong Second People's Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shandong Second People's Hospital. Primary endpoint: Objective Response Rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500113105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113105.